MMorgan Stanley TTesla · TSLA

Morgan Stanley Downgrades Tesla’s Rating to Equalweight

Dec 8, 2025· 1 min read· Reproduced verbatim
Rating
Buy
Price target
$425
Previous
$410
Implied downside
-7%

Morgan Stanley analyst Andrew Percoco downgraded Tesla from Overweight to Equalweight with a price target of $425 (from $410).

“Assuming coverage of TSLA at Equal-weight, with a $425 price target, implying 6% downside.

Tesla is a clear global leader in electric vehicles, manufacturing, renewable energy, and real world AI and thus deserving of a premium valuation.

However, high expectations on the latter have brought the stock closer to fair valuation.

While it is well understood that Tesla is more than an auto manufacturer, we expect a choppy trading environment for the TSLA shares over the next 12 months, as we see downside to estimates, while the catalysts for its non-auto businesses appear priced at current levels, driving our EW rating.

We’ve conducted a full re-calibration of our Tesla model, adding in Humanoid valuation supported by our Morgan Stanley Global Humanoid team’s TAM work, expanding our robotaxi model with a proprietary market analyses, broadening our Network Services (including FSD) model, moderating our Auto and Energy forecasts, and a building an illustrative pay package dilution analysis.

Disclaimer
The price target and rating on this page are the opinion of the issuing research firm and its analyst, not of Price Target. This page is published for informational purposes only and is not investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consider your own circumstances and consult a licensed financial adviser before making investment decisions.

This research note is reproduced verbatim from the issuing firm. Price Target never edits, paraphrases or alters analysts’ words — we only republish them in one place.

Share

Share on
Price Target is an archive of Wall Street analyst research, published for informational purposes only. Nothing on this site is investment advice, a recommendation, or an offer to buy or sell any security. Analyst ratings and price targets are the opinions of the issuing firms, not of Price Target. Always do your own research or consult a licensed financial adviser.